Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.

JASPERS, Aurélie; Baron, Frédéric; Maertens, Johan; DE PRIJCK, Bernard; Schots, Rik; Bonnet, Christophe; HAFRAOUI, Kaoutar; WILLEMS, Evelyne; SERVAIS, Sophie; FILLET, Georges; Beguin, Yves

doi:10.1002/ajh.24013

Letter to the editor (Scientific journals)

Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.

JASPERS, Aurélie; Baron, Frédéric; Maertens, Johan et al.

2015 • In American Journal of Hematology, 90 (7), p. 133-4

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/179794

DOI
10.1002/ajh.24013

PubMed
25802012

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Jaspers - AJH 2015.pdf

Publisher postprint (230.62 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

autologous hematopoietic cell transplantation; Darbepoetin alpha; survival; erythropoietin therapy; intravenous iron

Disciplines :

Hematology

Author, co-author :

JASPERS, Aurélie ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Baron, Frédéric ; Université de Liège - ULiège > GIGA-R : Hématologie

Maertens, Johan; University Hospital Gasthuisberg, Leuven, Belgium > Clinical Hematology > Acute Leukemia & Stem Cell Transplantation Unit

DE PRIJCK, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Schots, Rik; Universitair Ziekenhuis Brussel, Belgium > Department of Clinical Hematology and Stem Cell Laboratory

Bonnet, Christophe ; Université de Liège - ULiège > GIGA-R : Hématologie

HAFRAOUI, Kaoutar ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

WILLEMS, Evelyne ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

SERVAIS, Sophie ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

FILLET, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Beguin, Yves ; Université de Liège - ULiège > GIGA-R : Hématologie

Language :

English

Title :

Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.

Publication date :

July 2015

Journal title :

American Journal of Hematology

ISSN :

0361-8609

eISSN :

1096-8652

Publisher :

Wiley Liss, Inc., New York, United States - New York

Volume :

Issue :

Pages :

E133-4

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 30 March 2015

Statistics

Number of views

87 (8 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Beguin Y, Maertens J, De Prijck B, et al. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: A prospective multicenter randomized trial. Am J Hematol 2013;88:990-996.
Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009;373:1532-1542.
Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924.
Beguin Y, Aapro M, Ludwig H, et al. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis-A critical review. Crit Rev Oncol Hematol 2014;89:1-15.
Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-315.
Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 2012;106:1249-1258.